CD27 Immune Checkpoint Molecule for Drug Development

Immune Checkpoint CD27

CD27, also known as S152, LPFS2, T14, TNFRSF7, or Tp55, is a member of the tumor necrosis factor (TNF) receptor superfamily. It can be expressed on a wide battery of cell types, such as T cells, natural killer cells (NKs), and B cells. CD27 can bind to its ligand, CD70 (CD27L, TNFSF7), and interact with apoptosis regulatory protein Siva (SIVA1), TNF receptor-associated factor 2 (TRAF2), TRAF3, as well as TRAF5. Previous studies have demonstrated that CD27 plays an important role in mediating the activation of T cells, B cells, or NK cells and the synthesis of immunoglobulin. Moreover, this receptor is also essential to regulating cell apoptosis or cell death.

Checkpoint receptor Alternate name Cell type affected Ligand The function of ligand-receptor interaction
CD27 S152, T14, TNFRSF7, Tp55, CD27 molecule T cells, B cells, NK cells CD70 (CD27L, TNFSF7) Co-stimulatory

Structure of CD27

CD27 is a transmembrane phosphoglycoprotein of approximately 120 kDa and consists of a disulfide bond and two monomers. In general, it has an elongated, stepped structure consisting of cysteine-rich domains (CRDs), each of which has about 40 residues. CRD domain 1 includes residues 1-43, CRD domain 2 contains residues 44-85, and CRD domain 3 contains residues 86-101. CRD1 and CRD2 are all composed of three disulfides, while CRD3 only has two disulfides. Specific internal disulfides cross-link every CRD domain in an AABCBC pattern. Unlike CD27, its ligand CD70 is made up of a trimeric structure, and each subunit can interact with all CD27 homodimers.

Structure of CD27. Fig.1 Structure of CD27. (Teplyakov, 2017)

CD27 Immune Checkpoint Molecule for Drug Development

CD27, a transmembrane glycoprotein, is critical for cell growth and differentiation. Meanwhile, pilot studies have suggested that CD27-involved pathways play an immune costimulatory role and have been broadly used for treating various diseases. Furthermore, its ligand CD70 can be found in a range of malignant tumors, including lung cancer, ovarian cancer, renal cancer, glioblastoma, diffuse large B-cell lymphoma (DLBCL), and non-Hodgkin's lymphoma (NHL). As a result, targeting the CD27/CD70 immune checkpoint molecule has become an attractive strategy for drug development in disease immunotherapy.

Nowadays, a variety of CD27/CD70 drugs, like anti-CD27 antibodies and small-molecule drugs, have been generated and evaluated in many disease models. For example, the safety and efficacy of a human monoclonal antibody (mAb) against CD27 has been evaluated by different clinical trials of prostate cancer, ovarian cancer, and non-small-cell lung cancer (NSCLC). The data have indicated that anti-CD27 mAb can achieve strong antitumor immune-modulating activities in patients with B-cell lymphoma. Therefore, Creative Biolabs has established a comprehensive immune checkpoint-based drug discovery platform to provide a panel of services for immune checkpoint CD27.

Please feel free to contact us for more information.


  1. Teplyakov, A.; et al. Crystal structure of CD27 in complex with a neutralizing noncompeting antibody. Acta Crystallographica Section F: Structural Biology Communications. 2017, 73(5): 294-299.

All listed customized services & products are for research use only, not intended for pharmaceutical, diagnostic, therapeutic, or any in vivo human use.